Seroatlas · Human Serome Atlas

FPR3

N-formyl peptide receptor 3

Also known as: FMLPY, FPR3_HUMAN, FPRH1, FPRL2, RMLP-R-I

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P25089
Gene: FPR3
Ensembl: ENSG00000187474
Chromosome: 19
Canonical length: 353 aa
Protein class: G-protein coupled receptors, Predicted membrane proteins

OverviewNCBI Gene

Predicted to enable N-formyl peptide receptor activity and complement receptor activity. Predicted to be involved in several processes, including complement receptor mediated signaling pathway; phospholipase C-activating G protein-coupled receptor signaling pathway; and positive regulation of cytosolic calcium ion concentration. Predicted to act upstream of or within G protein-coupled receptor signaling pathway. Predicted to be located in membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

353 residues, UniProt reviewed canonical sequence.

>P25089|FPR3
     1  METNFSIPLN ETEEVLPEPA GHTVLWIFSL LVHGVTFVFG VLGNGLVIWV AGFRMTRTVN
    61  TICYLNLALA DFSFSAILPF RMVSVAMREK WPFGSFLCKL VHVMIDINLF VSVYLITIIA
   121  LDRCICVLHP AWAQNHRTMS LAKRVMTGLW IFTIVLTLPN FIFWTTISTT NGDTYCIFNF
   181  AFWGDTAVER LNVFITMAKV FLILHFIIGF SVPMSIITVC YGIIAAKIHR NHMIKSSRPL
   241  RVFAAVVASF FICWFPYELI GILMAVWLKE MLLNGKYKII LVLINPTSSL AFFNSCLNPI
   301  LYVFMGRNFQ ERLIRSLPTS LERALTEVPD SAQTSNTDTT SASPPEETEL QAM

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FPR3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.33
Highest tissue expression: 27 nTPM

Expression across tissuesHPA

Tissue

lung: 27 nTPM
appendix: 23 nTPM
liver: 20 nTPM
gallbladder: 18 nTPM
rectum: 17 nTPM
urinary bladder: 16 nTPM

Single-cell type

cdc: 304 nCPM
macrophages: 236 nCPM
kupffer cells: 197 nCPM
monocytes: 75 nCPM
epicardial cells: 21 nCPM
hepatic stellate cells: 19 nCPM

Immune cell

intermediate monocyte: 6.7 nTPM
myeloid DC: 2.4 nTPM
classical monocyte: 2.3 nTPM
total PBMC: 0.5 nTPM
neutrophil: 0.1 nTPM
plasmacytoid DC: 0.1 nTPM

Brain region

thalamus: 15 nTPM
white matter: 9.2 nTPM
medulla oblongata: 7.3 nTPM
pons: 7.3 nTPM
choroid plexus: 5.4 nTPM
spinal cord: 3.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD missense Z: 1.14
DepMap mean gene effect: 0.07
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FPR3 as an antibody target. Whether an autoantibody or antibody against FPR3 could matter depends on whether native FPR3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FPR3 is annotated at the cell surface, where native FPR3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label FPR3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...